The landscape of drug discovery is undergoing a seismic shift. For decades, the path from preclinical animal research to clinical trials has been defined by a linear, resource-intensive process: conduct a study, analyze the tissue, write a report, and archive the glass slides. However, the maturation of digital pathology—accelerated by the logistical demands of the COVID-19 pandemic—is transforming these legacy archives from "dead storage" into vibrant, data-rich assets.
By leveraging advanced computational techniques, researchers are now mining digitized tissue samples to extract molecular insights, train diagnostic models, and create "virtual" control groups. This evolution not only optimizes the information harvested from every animal model but also aligns with an aggressive global regulatory push to minimize animal testing in favor of New Approach Methodologies (NAMs).
Main Facts: The Digital Transformation of Histology
At the heart of this transformation is the transition from physical glass slides to high-resolution digital pixels. Historically, a pathology report was the final word on a study. Today, a digitized slide serves as a primary data source capable of answering questions that were not even contemplated when the original study was conducted.
Aleksandra Zuraw, DVM, PhD, a veterinary pathologist at Charles River Laboratories, encapsulates this shift: “Before, the pathology endpoint was just a report. Now, you have the digitized slide, which is essentially a massive dataset of pixels.”
By pairing these digital images with existing pathology reports and molecular metadata, scientists can train machine learning models to identify subtle biological patterns. This process allows for:
- Virtual Control Groups: By utilizing robust historical datasets, researchers can replace a portion of concurrent control animals, significantly reducing the total number of animals required for toxicology assessments.
- Molecular Retrospective Analysis: Using Formalin-Fixed, Paraffin-Embedded (FFPE) blocks—the standard storage method for tissue—researchers can perform molecular testing long after the initial experiment concludes, clarifying how specific drugs influenced cellular mechanisms.
- Virtual Staining: Emerging software now allows researchers to generate the appearance of stains on unstained tissue sections, potentially bypassing traditional, time-consuming laboratory protocols.
A Chronology of Progress: From Pandemic Necessity to Regulatory Standard
The rise of digital pathology has not been an overnight success, but rather a trajectory marked by necessity and technological convergence.
2020–2021: The Pandemic Catalyst
When global lockdowns restricted access to physical laboratories, digital pathology shifted from a niche convenience to an operational necessity. Pathologists, forced to work remotely, moved their diagnostic workflows to high-resolution monitors. This mass migration created a critical mass of digitized slide archives, providing the raw material for future AI-driven analysis.
2022: The FDA Modernization Act 2.0
The legislative landscape changed dramatically with the enactment of the FDA Modernization Act 2.0. This milestone law officially allowed for the use of non-animal methods to support drug development applications. It signaled a clear intent from regulators: the "gold standard" of animal testing was no longer the only acceptable path to human trials.
2024–2025: Strategic Institutional Shifts
In April 2024, Charles River Laboratories launched its Alternative Methods Advancement Project, a strategic initiative aimed at integrating these new technologies into the core of preclinical research. By 2025, the Organisation for Economic Co-operation and Development (OECD) released updated guidance on sample collection for omics analysis, providing a technical framework for how preserved tissue could support advanced molecular investigations.
2026: The New Regulatory Roadmap
In September 2026, the FDA provided updated regulations further codifying the use of innovative alternatives to animal testing. This followed an April 2025 roadmap that set a multi-year goal: to transition animal studies from a baseline requirement to the exception, with NAMs serving as the new industry default for safety testing.
Supporting Data: Efficiency Through Algorithmic Precision
The efficiency gains inherent in this new model are quantifiable. In a standard toxicology study, control groups occupy a significant portion of the animal population. By establishing that historical data is sufficiently comparable to current conditions, "virtual control groups" can be utilized to maintain statistical power while reducing the number of animals used.
However, this transition requires rigorous validation. Researchers must prove that the environmental conditions, genetic backgrounds, and handling procedures of historical cohorts align with current standards. Zuraw notes that the effort is currently focused on “generating enough matched data to provide virtual controls wherever it is possible.”
Furthermore, the quality of molecular findings is dependent on the integrity of the archived tissue. While fresh-frozen samples are often preferred for certain molecular analyses, the use of FFPE blocks—when coupled with high-throughput sequencing and digital imaging—allows researchers to extract "context-rich" data without the need for additional prospective animal experiments. As the 2025 OECD guidelines suggest, meticulous sample preparation and storage are the keys to ensuring that archived materials remain viable for high-fidelity molecular investigations.
Official Responses and Industry Perspectives
The industry response to these developments has been one of cautious, yet rapid, adoption. For large-scale research organizations like Charles River, the focus is on creating a "snowball effect." By proving the efficacy of digital-first workflows in early studies, these organizations are building a body of evidence that regulators and peer reviewers can trust.
Dr. Zuraw’s work, including her engagement with thought leaders like Dr. Syed T. Hoda of NYU, highlights the importance of "digital sign-out"—the process of fully adopting digital tools for primary diagnosis. The goal is to move the industry toward a state where the digitized image is the primary evidence, and the glass slide is merely the secondary backup.
"You still need enough early adopters to generate precedent," Zuraw explains. "Those early adopters will embrace the guidance, figure it out and troubleshoot, and then others can build on their work without reinventing the wheel."
Implications for the Future of Drug Development
The shift toward mining existing tissue archives has profound implications for the ethics and speed of drug discovery.
1. Ethical Stewardship (The 3Rs)
The primary implication is the advancement of the "3Rs" (Replacement, Reduction, and Refinement). By extracting more information from the same animals, researchers are fundamentally reducing the total number of lives required to bring a new therapy to market. This satisfies both growing public demand for ethical research and the increasing cost-efficiency mandates of the pharmaceutical industry.
2. Scientific Depth
The ability to return to an archive when a new scientific question arises changes the nature of the "hypothesis." Previously, a failure to plan for a specific molecular measurement meant the experiment was a "dead end." Now, the archive functions as a longitudinal database. If a researcher identifies a new biomarker in 2028, they can re-examine samples from a 2026 toxicology study to see if that marker was present, effectively "retroactively" improving the original study.
3. Regulatory Standardization
The FDA’s long-term roadmap aims for a transition period of three to five years. For biotechnology and pharmaceutical companies, this means that the "new" way of working—using digital slides and virtual controls—will soon be the standard expected in regulatory filings. Companies that fail to invest in the infrastructure for digital pathology and bioinformatics risk being left behind, both in terms of regulatory compliance and operational speed.
4. The Path to "Virtual" Histology
Beyond just digitizing existing slides, the rise of virtual staining technologies suggests a future where the physical laboratory footprint could shrink. If software can reliably simulate the staining process, the reliance on chemical dyes and physical slide preparation will diminish. While we are currently in the transition phase of "digitizing the glass," the next phase will likely be the "elimination of the glass" entirely.
Conclusion
The digital pathology revolution is moving beyond the simple convenience of remote diagnosis. It has become a cornerstone of a modern, data-driven, and ethically responsible approach to drug discovery. By unlocking the wealth of information trapped within millions of archived tissue blocks, the scientific community is finding a way to accelerate innovation while simultaneously lowering the reliance on animal models. As researchers continue to refine these methodologies, the "snowball effect" predicted by experts will likely solidify this digital-first approach as the bedrock of 21st-century preclinical research.
About the Author
